Skip to main content
NVDA+0.57%AAPL+0.41%GOOGL+0.93%MSFT+0.39%AMZN+0.36%TSM-0.16%SPCX+1.09%META+0.17%AVGO-1.10%TSLA+0.05%SKHY-1.36%MU+0.23%LLY-2.33%BRK-B-0.88%AMD+0.69%JPM-1.24%WMT-2.70%ASMLa-0.27%XOM+0.87%V-1.79%JNJ-1.06%INTC+3.71%0700.HK-0.23%MA-2.15%1398.HK+0.78%ABBV-0.65%CSCO+0.65%LRCX+1.44%CVX-0.08%AMAT-0.12%COST-1.54%AP2d+1.46%ORCL-0.35%BAC-0.96%CAT-1.92%KO-0.88%DELL-0.30%0005.HK-0.63%PG-2.05%HSBA.L-0.64%UNH-2.10%3988.HK+1.16%GE-1.76%1816.HK+0.48%ARM-1.37%0857.HK-0.51%0939.HK+1.34%1288.HK+0.61%PM-1.59%MS-2.43%GBPAUD+1.15%AUDUSD-1.11%GBPCHF+1.02%USDCHF+0.96%GBPCAD+0.78%GBPNZD+0.78%NZDUSD-0.75%USDCAD+0.75%EURGBP-0.66%GBPJPY+0.64%EURUSD-0.62%USDJPY+0.59%USDTHB+0.58%AUDJPY-0.54%EURAUD+0.51%PLNJPY+0.44%GBPTRY+0.41%SGDJPY+0.39%AUDCAD-0.39%AUDNZD-0.36%EURCHF+0.33%CHFJPY-0.33%NOKJPY+0.32%GBPHKD+0.32%USDTRY+0.29%GBPMXN-0.28%CADCHF+0.22%NZDCHF+0.21%AUDNOK+0.21%USDNOK+0.18%NZDMXN-0.18%AUDCHF-0.18%USDILS+0.16%EURNZD+0.14%NZDJPY-0.14%CADJPY-0.14%AUDSGD+0.13%EURCAD+0.12%USDSGD+0.11%USDCNH-0.11%EURNOK+0.11%NZDSGD-0.10%CHFNOK+0.10%AUDDKK+0.10%EURHKD-0.10%USDZAR+0.10%USDSEK+0.09%USDDKK+0.08%USDPLN+0.07%USDMXN+0.06%GBPUSD+0.04%USDCOP-0.04%EURSGD+0.03%USDHKD+0.03%EURJPY-0.03%CHFSGD+0.03%EURCZK+0.03%GBPSGD+0.02%CHFSEK+0.01%EURSEK+0.01%EURZAR+0.01%NZDCAD-0.01%EURPLN0.00%GBPZAR0.00%EURCNH0.00%EURDKK0.00%USOIL-1.41%GAGUSD+1.28%XAGUSD+1.28%UKOIL-1.17%S1-0.62%XNGUSD-0.59%XAUUSD+0.50%GAUUSD+0.50%XPTUSD+0.44%HG1-0.39%C1-0.37%COTTON-0.35%BTCUSD+0.57%ETHUSD+7.44%USDTUSD-0.03%XRPUSD+0.63%SOLUSD-0.64%TRXUSDT+0.92%ZECUSDT+1.58%DOGEUSD-0.17%LINKUSD-2.08%XMRUSDT+1.39%XLMUSD+3.07%BCHUSDT+0.53%UNIUSD+1.15%LTCUSD+0.07%HBARUSDT+4.15%SUIUSD+2.05%TONUSD+15.77%TAOUSDT+2.72%AAVEUSD+0.86%DOTUSDT+4.63%ICPUSDT-1.17%ONDOUSDT+2.03%WLDUSDT+9.89%ARBUSDT+1.53%JUPUSDT+0.41%ATOMUSDT+2.73%INJUSDT-0.40%STXUSDT+25.59%FETUSDT+5.52%SEIUSDT+1.69%PYTHUSDT-0.17%TIAUSDT+2.65%IMXUSDT+3.40%GRTUSDT+2.07%OPUSDT+2.09%WIFUSDT+4.29%IOTAUSDT+7.44%POLUSDT-3.39%AXSUSDT+1.28%FARTCOINUSDT+0.50%EOSUSDT+4.55%DYDXUSDT+5.13%GALAUSDT+3.85%ORDIUSDT+2.69%NOTUSDT+2.57%RONINUSDT+3.21%NVDA+0.57%AAPL+0.41%GOOGL+0.93%MSFT+0.39%AMZN+0.36%TSM-0.16%SPCX+1.09%META+0.17%AVGO-1.10%TSLA+0.05%SKHY-1.36%MU+0.23%LLY-2.33%BRK-B-0.88%AMD+0.69%JPM-1.24%WMT-2.70%ASMLa-0.27%XOM+0.87%V-1.79%JNJ-1.06%INTC+3.71%0700.HK-0.23%MA-2.15%1398.HK+0.78%ABBV-0.65%CSCO+0.65%LRCX+1.44%CVX-0.08%AMAT-0.12%COST-1.54%AP2d+1.46%ORCL-0.35%BAC-0.96%CAT-1.92%KO-0.88%DELL-0.30%0005.HK-0.63%PG-2.05%HSBA.L-0.64%UNH-2.10%3988.HK+1.16%GE-1.76%1816.HK+0.48%ARM-1.37%0857.HK-0.51%0939.HK+1.34%1288.HK+0.61%PM-1.59%MS-2.43%GBPAUD+1.15%AUDUSD-1.11%GBPCHF+1.02%USDCHF+0.96%GBPCAD+0.78%GBPNZD+0.78%NZDUSD-0.75%USDCAD+0.75%EURGBP-0.66%GBPJPY+0.64%EURUSD-0.62%USDJPY+0.59%USDTHB+0.58%AUDJPY-0.54%EURAUD+0.51%PLNJPY+0.44%GBPTRY+0.41%SGDJPY+0.39%AUDCAD-0.39%AUDNZD-0.36%EURCHF+0.33%CHFJPY-0.33%NOKJPY+0.32%GBPHKD+0.32%USDTRY+0.29%GBPMXN-0.28%CADCHF+0.22%NZDCHF+0.21%AUDNOK+0.21%USDNOK+0.18%NZDMXN-0.18%AUDCHF-0.18%USDILS+0.16%EURNZD+0.14%NZDJPY-0.14%CADJPY-0.14%AUDSGD+0.13%EURCAD+0.12%USDSGD+0.11%USDCNH-0.11%EURNOK+0.11%NZDSGD-0.10%CHFNOK+0.10%AUDDKK+0.10%EURHKD-0.10%USDZAR+0.10%USDSEK+0.09%USDDKK+0.08%USDPLN+0.07%USDMXN+0.06%GBPUSD+0.04%USDCOP-0.04%EURSGD+0.03%USDHKD+0.03%EURJPY-0.03%CHFSGD+0.03%EURCZK+0.03%GBPSGD+0.02%CHFSEK+0.01%EURSEK+0.01%EURZAR+0.01%NZDCAD-0.01%EURPLN0.00%GBPZAR0.00%EURCNH0.00%EURDKK0.00%USOIL-1.41%GAGUSD+1.28%XAGUSD+1.28%UKOIL-1.17%S1-0.62%XNGUSD-0.59%XAUUSD+0.50%GAUUSD+0.50%XPTUSD+0.44%HG1-0.39%C1-0.37%COTTON-0.35%BTCUSD+0.57%ETHUSD+7.44%USDTUSD-0.03%XRPUSD+0.63%SOLUSD-0.64%TRXUSDT+0.92%ZECUSDT+1.58%DOGEUSD-0.17%LINKUSD-2.08%XMRUSDT+1.39%XLMUSD+3.07%BCHUSDT+0.53%UNIUSD+1.15%LTCUSD+0.07%HBARUSDT+4.15%SUIUSD+2.05%TONUSD+15.77%TAOUSDT+2.72%AAVEUSD+0.86%DOTUSDT+4.63%ICPUSDT-1.17%ONDOUSDT+2.03%WLDUSDT+9.89%ARBUSDT+1.53%JUPUSDT+0.41%ATOMUSDT+2.73%INJUSDT-0.40%STXUSDT+25.59%FETUSDT+5.52%SEIUSDT+1.69%PYTHUSDT-0.17%TIAUSDT+2.65%IMXUSDT+3.40%GRTUSDT+2.07%OPUSDT+2.09%WIFUSDT+4.29%IOTAUSDT+7.44%POLUSDT-3.39%AXSUSDT+1.28%FARTCOINUSDT+0.50%EOSUSDT+4.55%DYDXUSDT+5.13%GALAUSDT+3.85%ORDIUSDT+2.69%NOTUSDT+2.57%RONINUSDT+3.21%
CE

Celcuity Inc. (CELC)

NASDAQ • Healthcare

$79.52
+$2.14 (+2.8%)
Market closed

Last close at September 30, 2026 at 20:00 UTC

Open$81.3
Day Range$77.84 - $88.68
Avg. Volume (3M)963.6K
Market Cap$3.8B
52 Week Range
$44.42$151.02
Next EarningsIn 41 daysNov 11, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)
$0
Net Income (TTM)
-$226.4M
EPS (TTM)
-$4.29
ROA (TTM)
-27.35%
Current Ratio
8.93

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+8.5%Q1 2026-$0.97
+6.7%Q2 2026-$0.97
-24.1%Q3 2026-$1.44
Next

Nov 11

in 41 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -24.1%

Celcuity’s EPS trailed the $-1.16 consensus in the second fiscal quarter of 2026, and the Aug. 13 report was based on preliminary results. EPS came in at $-1.44, missing by 24.1% and down 38.5% from $-1.04 a year ago. Operating income was a loss of about $66.1 million, while net income fell 74.2% to a loss of about $78.9 million from $45.3 million a year earlier; operating cash flow was negative $55.4 million. Consensus for the next period calls for EPS of $-1.11 on revenue of $5.1 million.

View full earnings history

About Celcuity Inc.

Celcuity Inc. is a NASDAQ-listed healthcare company in biotechnology that discovers new cancer sub-types and commercializes diagnostic tests for patients treated with targeted therapies. Founded in 2012, Celcuity operates as an early-stage oncology diagnostics business from Minneapolis, Minnesota, focused on precision cancer classification and testing.

Name
Celcuity Inc.
CEO
Brian F. Sullivan
Website
www.celcuity.com
Industry
Healthcare
Year Founded
2012
Employees
155

Today's Snapshot

AI-generated

CELC closed 2.8% higher on heavier trading than usual. Celcuity announced REVTORPYK, a cancer treatment, is now available in the U.S.

Trading Volume

Above 10d avg 1.0M

2.5M

vs S&P 500 Today

Outperforming Market

+2.58%

Updated: September 30, 2026 at 20:12 UTC

CELC Headlines

FDA clears Celcuity’s Revtorpyk for breast cancer

July 14, 2026

3 min read

Valuation Gaps Emerge Across Key Mid‑Cap Stocks

February 16, 2026

7 min read
View All News

Technical Indicators

1 Buy1 Neutral6 Sell
CELC is rated a strong sell as of the latest close, with short-term momentum indicators showing bearish bias while longer-run moving averages sit well above the current price of 79.52. Momentum measures and the MACD register clear negative readings, and the ADX near the mid-20s indicates only moderate trend strength rather than a decisive reversal. Volatility is elevated with an ATR around 5.5% of price, and although OBV shows accumulation, the price remains under multiple short- and long-term averages and only marginally above the classic pivot. Technical takeaway: Strong Sell.
All signals
  • EMA (5 indicators)$80.86 - $95.88
    Sell
  • RSI (14)39.42
    Neutral
  • Stochastic %K (14, 3, 3)12.99
    Buy
  • MACD Level (12, 26)-3.28
    Sell

Peers & Related Assets

APGEApogee Therapeutics, Inc.
$135.07-0.0%
CGONCG Oncology Inc.
$70.89+0.5%
TVTXTravere Therapeutics, Inc.
$58.88-1.9%
XENEXenon Pharmaceuticals Inc.
$37.19-0.2%
IRONDisc Medicine, Inc.
$65.46-0.6%
RAREUltragenyx Pharmaceutical Inc.
$15.03-1.9%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.